CroíValve Secures $27M Extension to Series B Funding to Expand DUO Adapt Clinical Study
CroíValve
Medical Device Developer
Irrus Investments
Angel Investment Firm
Ascentifi
Early-Stage Investment Firms
MedTech Syndicates
--
European Innovation Council
The European Innovation Council (EIC) was established by the European Commission to support the commercialization of high-risk, high-impact technologies within the EU. The fully operational EIC was launched in March 2021 under Horizon Europe and is integrated into the European Innovation Council and SMEs Executive Agency. Its objective is to help researchers, startups, and small and medium-sized enterprises bring their innovations to market by providing funding, networking and collaboration opportunities, and business acceleration services.
Disruptive Technology Innovation Fund
Government Startup Assistance Fund
Irish medtech company CroíValve completes $36 million Series B financing, bringing total funding to $43 million. The round was co-led by MedTech Syndicates and Irrus Investments, with existing investors such as Ascentifi participating in the follow-on investment, and IAG Capital Partners joining as a new investor.
The proceeds from the financing will be used to expand the scale of the TANDEM II clinical trial, which aims to evaluate the clinical performance of the investigational DUO Adapt System for tricuspid regurgitation. The preceding TANDEM I trial demonstrated that the device significantly reduces the severity of tricuspid regurgitation and improves patients’ quality of life, restoring cardiac function without requiring removal of the patient’s native valve structures.
Tricuspid regurgitation is a severe cardiac disease, with the total number of patients in Europe and America exceeding 4 million.
CroíValve also announced that Tim Rea of BGF has joined its Board of Directors.
The translated content is provided by third-party software.
Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For accurate information, please refer to official announcements. If you have any questions, please contact: biz@staff.sina.com.cn.
Responsible Editor: Xiaolang Express